contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


inhalation-sciences-to-present-abstracts-from-the-fda-funded-evaluation-study-on-dissolvitr-and-the-aprinha-project-at-the-2025-ddl-conference

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Inhalation Sciences Sweden, ISAB, is a research company. The company focuses primarily on the production and development of laboratory instruments. The instruments are used to measure particles in inhaled air and how the composition of the air affects the lungs. The company sells products under various brands, mainly on the European market. Inhalation Sciences Sweden was founded in 2004 and is headquartered in Huddinge.

Inhalation Sciences Sweden

Inhalation Sciences AB (ISAB) today announced that both of its submitted abstracts have been accepted for presentation at the upcoming Drug Delivery to the Lungs (DDL) Conference in December...

<div class="abstract">Inhalation Sciences AB (ISAB) today announced that both of its submitted abstracts have been accepted for presentation at the upcoming Drug Delivery to the Lungs (DDL) Conference in December. ISAB's Chief Scientific Officer and founder, Assoc. Professor. Per Gerde and Director of Projects, PhD Maria Malmlöf, will present results from two major research initiatives, highlighting the company's latest advances in inhalation drug development.</div>This recognition underscores ISAB's continued leadership in advancing cutting-edge research within inhaled drug development.Assoc. Professor. Per Gerde, will have a podium presentation on the pharmacokinetic (PK) studies from the European research project "New Inhalation Formulations for Improved Delivery of Antimicrobials" (APRINHA). The APRINHA project is developing and evaluating five innovative formulations of the antibiotic apramycin, aiming to create an effective inhaled antibiotic treatment for lower respiratory tract infections (LRTIs), including those caused by antibiotic-resistant bacteria. ISAB was selected to conduct the pharmacokinetic studies in the APRINHA project due to the unique precision and capabilities of its proprietary PreciseInhale® platform technology.The APRINHA project is coordinated by the University of Zurich and brings together leading academic and industry partners across Europe.Furthermore, PhD Maria Malmlöf will present the results from the FDA-funded evaluation study of ISAB's in vitro dissolution module, DissolvIt®. This study demonstrates that DissolvIt® generates pharmacokinetic (PK) data capable of predicting clinical plasma profiles, supporting its use in bioequivalence assessments.In addition to the DDL conference, Inhalation Sciences will also be exhibiting at the upcoming MVIC inhalation symposium in Lund on October 8-9, where company representatives will be available at their booth to discuss these studies and broader research into advanced pulmonary drug delivery technologies.For more information, please contact: Manoush Masarrat, CEO Phone: +46 (0) 73 628 9153 E-mail: manoush.masarrat@inhalation.seAbout Inhalation Sciences Sweden AB (publ) Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&amp;D pipelines by delivering high-resolution, predictive data early in the development process.<div></div>

Inhalation Sciences to Present abstracts from the FDA-Funded Evaluation Study on DissolvIt® and the APRINHA Project at the 2025 DDL Conference